Chromenone derivatives
AssigneeAstraZeneca AB
InventorsBernard Christophe BARLAAM, Sebastien Louis DEGORCE, Christine Marie, Paul LAMBERT-VAN DER BREMPT, Remy Robert MORGENTIN, Patrick PLE
Life of this patent
Estimating the term…
Abstract
The invention concerns chromenone derivatives of Formula I or a pharmaceutically-acceptable salts thereof, wherein each of R1, R2, R3, R4, R5, R6, R7, R8, n and R9 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
Claims9
-8. (canceled)
A method for treating cancer in a warm blooded animal in need thereof comprising administering to the animal an effective amount of 8-((1R)-1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-5 carboxamide, or a pharmaceutically acceptable salt thereof in combination with an antiandrogen.
A method for treating cancer in a warm blooded animal in need thereof comprising administering to the animal an effective amount of 8-((1R)-1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-5 carboxamide, or a pharmaceutically acceptable salt thereof in combination with a taxoid.
A method for treating cancer in a warm blooded animal in need thereof comprising administering to the animal an effective amount of 8-((1R)-1-(3,5-difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-5 carboxamide, or a pharmaceutically acceptable salt thereof in combination with a MEK kinase inhibitor.
Dependencies are inferred from the claim text.